Impact of vitamin D supplementation on the clinical outcomes of COVID-19 pneumonia patients: a single-center randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Vitamin D supplementation for infectious diseases has been discussed, but its role in COVID-19 is unclear.

Therefore, this study examined the clinical outcomes of COVID-19 pneumonia patients who received vitamin D supplementation.

Who Took Part

According to the abstract, 19 patients were involved.

The inclusion criteria were patients aged ≥ 18 years with COVID-19 pneumonia patients.

The clinical outcomes were pneumonia treatment duration, length of hospital stay, and change in pneumonia severity index between enrollment and discharge.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

This prospective, open-label, randomized controlled trial was conducted in a university hospital between July 2020 and March 2022.

What Was Measured

Therefore, this study examined the clinical outcomes of COVID-19 pneumonia patients who received vitamin D supplementation.

The subject headings attached to it are COVID-19, SARS-CoV-2, C-Reactive Protein, Vitamin D, Dietary Supplements, Adrenal Cortex Hormones and Oxygen.

The authors tagged it with the keywords Alfacalcidol and Pneumonia.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (BMC complementary medicine and therapies), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.